Showing 3941-3950 of 4063 results for "".
- Ranibizumab and Aflibercept Prompt Comparable Visual Gain in AMDhttps://modernod.com/news/ranibizumab-and-aflibercept-prompt-comparable-visual-gain-in-amd/2476339/In patients with neovascular age-related macular degeneration (AMD), aflibercept and ranibizumab achieve similar average visual acuity increases, according Australian researchers, as reported by Reuters. In a January 24 online paper in JAMA Ophthalmology, Dr. Mark C. Gillies of Sy
- Bausch Health Reduces Debt By Additional $100 Millionhttps://modernod.com/news/bausch-health-reduces-debt-by-additional-100-million/2476341/Bausch Health Companies, the parent company of Bausch + Lomb, announced it has paid down an additional $100 million of its senior secured term loans using cash generated from operations. “As Bausch Health pivots to offense in 2019, we continue to remain
- Joe Garibaldi Appointed Vice President of US Sales at Optovuehttps://modernod.com/news/joe-garibaldi-appointed-vice-president-of-us-sales-at-optovue/2476172/Joe Garibaldi has been appointed to vice president of US Sales at Optovue, where he will continue to lead the US sales force as well as identify new strategic partnering opportunities to grow the company’s US product portfolio. Garibaldi joined Optovue in 2009 as a territory manager and he
- In Memoriam: Jack J. Kanski, FRCS, FRCOphthhttps://modernod.com/news/in-memoriam-jack-j-kanski-frcs-frcophth/2476199/World-renowned ophthalmologist Jacek Jerzy Kanski (better known as Jack J. Kanski, FRCS, FRCOphth) died on January 5, 2019. Few authors have left behind so vast a legacy. His books have enabled tens of thousands of ophthalmologists around the world to pass their examinations and have served as re
- Wize Pharma Announces Publication of LOA2 Data on Treatment of Moderately Severe Sjögren’s Syndrome-Related Dry Eyehttps://modernod.com/news/wize-pharma-announces-publication-of-loa2-data-on-treatment-of-moderately-severe-sjogrens-syndrome-related-dry-eye/2476200/Wize Pharma announced publication of data generated in an investigator initiated study conducted in Hungary during 2016, entitled “Treatment of Moderately Severe Sjögren’s Syndrome-Related Dry Eye without Immunomodulation: A Self-Controlled, Unmasked S
- Global Demand for Refractive Surgery Growing After Economic Rebound in Major Marketshttps://modernod.com/news/global-demand-for-refractive-surgery-growing-after-economic-rebound-in-major-markets/2476207/Global demand for refractive surgery is expected to grow at a compound annual rate of 5.2 percent from 2018 to 2023, with annual surgical volume increasing from 4.3 million to 5.5 million procedures, according to the latest Market Scope estimates. Demand for refractive surgery has continued to gr
- Staar Surgical Expects Fourth Quarter ICL Sales to Rise 42%; China Units Nearly Double, U.S. Market Returns to Growthhttps://modernod.com/news/staar-surgical-expects-fourth-quarter-icl-sales-to-rise-42-china-units-nearly-double-u-s-market-returns-to-growth/2476216/Staar Surgical, which provided preliminary sales results for the fourth quarter ending December 28, 2018, said it expects fourth quarter ICL net sales to increase approximately 42% over the prior year period. Total net sales for the fourth quarter are expected to be approximately $31.2 million an
- Oculis Raises $15.7 Million to Advance Development of Novel Topical Treatments for Ophthalmic Diseaseshttps://modernod.com/news/oculis-raises-15-7-million-to-advance-development-of-novel-topical-treatments-for-ophthalmic-diseases/2476221/Oculis announced that it has successfully raised a further 15.5 million Swiss Franc ($15.7 million) in an extension of its Series B financing round, announced in January 2018, bringing the total raised to 35.5 million Swiss Franc. The extension round was led by funds managed by Tekla Capital Mana
- Bausch + Lomb Announces Health Canada Approval Of Vyzulta for the Treatment of Glaucomahttps://modernod.com/news/bausch-lomb-announces-health-canada-approval-of-vyzulta-for-the-treatment-of-glaucoma/2476223/Bausch + Lomb announced that Health Canada issued a Notice of Compliance approving Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%) for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Vyzulta is the first prostaglandin analog with one of its metabolites
- Dompé Announces First Treatment with Oxervate Eye Drops for Neurotrophic Keratitis (NK)https://modernod.com/news/dompe-announces-first-treatment-with-oxervate-eye-drops-for-neurotrophic-keratitis-nk/2476224/Dompé announced the first treatment of a patient with Oxervate eye drops (cenegermin-bkbj) in the United States. Oxervate was approved by the FDA in August 2018 as the first drug specifically indicated to treat neurotrophic keratitis